Concord Drugs Ltd - 538965 - Board Meeting Intimation for The Audited Financial Results For The Quarter And Year Ended 31-03-2019
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2019 ,inter alia, to consider and approve the audited financial results for the quarter and year ended 31-03-2019 Concord Drugs Ltd - 538965 - Compliance With SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31.03.2019
Compliance with SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the half year ended 31.03.2019 Concord Drugs Ltd - 538965 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayConcord Drugs Ltd 2CININE858L01010 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: NOT APPOINTED Designation: NA EmailId: concorddrugsltd@gmail.com Name of the Chief Financial Officer: KONI REDDY SEELAM Designation: CFO EmailId: concorddrugsltd@gmail.com Date: 30/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Concord Drugs Ltd - 538965 - Shareholding for the Period Ended March 31, 2019
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here Concord Drugs Ltd - 538965 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Resignation of Company Secretary/Compliance officer Concord Drugs Ltd - 538965 - Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Monika BhuttadaDesignation :- Company Secretary and Compliance Officer Concord Drugs Ltd - 538965 - Intimation U/R 8(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015
The Company's Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information has been amended in accordance with the provisions of the SEBI (prohibition of Insider Trading) (Amended) Regulations, 2018. Concord Drugs Ltd - 538965 - Closure of Trading Window
The trading window for dealing in the securities of the Company will remain closed from 31st March, 2019 till 48 hours after the declaration of financial results for the quarter ended and year ended 31.03.2019, for all designated persons, their immediate relatives and all connected persons covered under the Company's Code of Conduct Concord Drugs Ltd - 538965 - Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of directors in independent category Concord Drugs Ltd - 538965 - Results-Financial Results For Quater Ended 31-12-2018
Results-financial results for quater ended 31-12-2018